Irritable Bowel Syndrome News

The amount of data presented at Digestive Disease Week 2015 regarding irritable bowel syndrome attests to the need and desire for more knowledge of this multi-faceted disease.

According to a recent clinical review, irritable bowel syndrome is the most commonly diagnosed gastrointestinal condition affecting 7% to 21% of the general population, though it is likely not a single disease but rather a “symptom cluster resulting from diverse pathologies.” As such, diagnosing IBS has traditionally been made by identifying key symptoms and excluding other organic diseases, while treatments have targeted symptoms rather than an underlying cause.

Synthetic Biologics Inc., a microbiome therapeutics developer, has announced a public offering of 13.3 million shares of common stock grossed at $40 million, according to a press release.

Recent analysis shows that individuals with panic and/or anxiety disorders had a higher prevalence of various physical illnesses compared with the general population.

Psychological factors, particularly anxiety, increased risk for developing infectious gastroenteritis, which in turn increased risk for postinfectious irritable bowel syndrome, according to new research data.

Results from a randomized controlled trial showed pinaverium bromide, an antispasmodic commonly used around the world but not currently approved by the FDA, quickly and safely reduces symptoms of irritable bowel syndrome.

A phase 2 clinical trial of SYN-010 for the treatment of irritable bowel syndrome with constipation has been initiated, the manufacturer announced.

Participation in a relaxation response based mind-body group intervention was associated with improvements in disease-specific measures, trait anxiety and pain catastrophizing in patients with irritable bowel syndrome and inflammatory bowel disease, according to study findings.

IBgard, a peppermint oil natural health product for relieving symptoms of irritable bowel syndrome, has received approval from Health Canada’s Natural and Non-Prescription Health Products Directorate, the manufacturer announced.

WASHINGTON — William D. Chey, MD, from the University of Michigan Health System discusses several abstracts he presented at DDW 2015 with data on new drug treatments for irritable bowel syndrome.